Current guidelines recommend that clopidogrel be given to patients for 12 months after drug-eluting stent (DES) implantation. However, the evidence is insufficient to support the benefit of long-term clopidogrel therapy, especially in Asian patients. The aim of this study was to evaluate whether different durations of clopidogrel use might influence long-term outcomes after DES implantation. A total of 844 patients from 4 medical centers in Korea who had undergone successful DES implantation from November 2004 to April 2006 were enrolled. Patients who were event free at 6-month follow-up were divided into 2 groups by clopidogrel use (575 users, 163 nonusers) and followed. The end point was a composite of death, myocardial infarction, and st...
BACKGROUND: The optimal duration of dual-antiplatelet therapy and the risk-benefit ratio for long-t...
Background Current recommendations for antithrombotic therapy after drug-eluting stent (DES) implant...
ObjectivesWe sought to define the incidence of late clinical events and late stent thrombosis in pat...
The risk of late thrombotic events and the need for prolonged dual antiplatelet therapy detract from...
Background: The optimal duration of clopidogrel use for prevention of stent thrombosis with drug-elu...
Background—Current guidelines recommend combining clopidogrel with aspirin for up to 1 year after co...
In patients presenting with acute coronary syndrome (ACS) the optimal duration of dual-antiplatelet ...
ObjectivesThe purpose of this study was to evaluate the risk of stent thrombosis (ST), clinical outc...
BACKGROUND: The impact of adherence to the recommended duration of dual antiplatelet therapy after f...
International audienceAIM:This open-label, randomized, and multicentre trial tested the hypothesis t...
ObjectivesThe purpose of this study was to determine whether long-term clinical outcomes differed be...
SummaryBackgroundClopidogrel has been utilized as an antiplatelet therapy for patients undergoing st...
Background: Twelve-month dual antiplatelet therapy (DAT) with aspirin and clopidogrel after drug-elu...
Four weeks' therapy with clopidogrel, in addition to aspirin (acetylsalicylic acid), is currently st...
AbstractBackgroundRecent large clinical trials show lower rates of late cardiovascular events by ext...
BACKGROUND: The optimal duration of dual-antiplatelet therapy and the risk-benefit ratio for long-t...
Background Current recommendations for antithrombotic therapy after drug-eluting stent (DES) implant...
ObjectivesWe sought to define the incidence of late clinical events and late stent thrombosis in pat...
The risk of late thrombotic events and the need for prolonged dual antiplatelet therapy detract from...
Background: The optimal duration of clopidogrel use for prevention of stent thrombosis with drug-elu...
Background—Current guidelines recommend combining clopidogrel with aspirin for up to 1 year after co...
In patients presenting with acute coronary syndrome (ACS) the optimal duration of dual-antiplatelet ...
ObjectivesThe purpose of this study was to evaluate the risk of stent thrombosis (ST), clinical outc...
BACKGROUND: The impact of adherence to the recommended duration of dual antiplatelet therapy after f...
International audienceAIM:This open-label, randomized, and multicentre trial tested the hypothesis t...
ObjectivesThe purpose of this study was to determine whether long-term clinical outcomes differed be...
SummaryBackgroundClopidogrel has been utilized as an antiplatelet therapy for patients undergoing st...
Background: Twelve-month dual antiplatelet therapy (DAT) with aspirin and clopidogrel after drug-elu...
Four weeks' therapy with clopidogrel, in addition to aspirin (acetylsalicylic acid), is currently st...
AbstractBackgroundRecent large clinical trials show lower rates of late cardiovascular events by ext...
BACKGROUND: The optimal duration of dual-antiplatelet therapy and the risk-benefit ratio for long-t...
Background Current recommendations for antithrombotic therapy after drug-eluting stent (DES) implant...
ObjectivesWe sought to define the incidence of late clinical events and late stent thrombosis in pat...